We believe the potential markets for regenerative medicine and stem cell therapy are large. The table below summarizes the potential United States patient populations which we believe may be amenable to cell or organ transplantation and represent target markets for products generated through our regenerative medicine technology.
| Medical Condition | Number of Patients* |
| Cardiovascular disease | 70 million |
| Autoimmune disease | 50 million |
| Diabetes | 18 million |
| Osteoporosis | 10 million |
| Cancer | 10 million |
| Alzheimer’s disease | 4.5 million |
| Parkinson’s disease | 1 million |
| Burns (severe) | 1.1 million |
| Spinal-cord injuries | .25 million |
| Birth defects | .15 million/year |
* These estimates are based on the most current patient estimates published by the following organizations as of April 2005: the American Heart Association, the American Autoimmune Related Diseases Association, SEER (Surveillance, Epidemiology and End Result), American Burn Association, March of Dimes, the Alzheimer’s Association, the Alzheimer’s Disease Education & Referral Center (National Institute on Aging), the National Institutes of Health’s National Institute on Neurological Disorders and Stroke, the Foundation for Spinal Cord Injury Prevention, Care & Cure, the Centers for Disease Control and Prevention, the American Association of Diabetes Educators, the Northwest Parkinson’s Foundation and the Parkinson’s Action Network.